Clonidine is a pharmaceutical drug used to treat a wide variety of conditions including hypertension, ADHD, insomnia, chemical withdrawal, and anxiety. Clonidine is often prescribed in combination with other drugs, depending on the clinical condition. This analytical reference standard is suitable for use as starting material in calibrators or controls for a variety of LC/MS or GC/MS applications from forensic analysis and clinical toxicology to pharmaceutical research.
法律資訊
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
British journal of anaesthesia, 111(2), 256-263 (2013-03-28)
A wide range of doses has been suggested for intrathecal clonidine, but no dose-ranging study has examined analgesic effects below 100 µg. The primary aim of this volunteer study was to assess the dose vs analgesic effect relationship for doses
International journal of obstetric anesthesia, 22(2), 133-145 (2013-03-13)
With over four million deliveries annually in the United States alone and a constant increase in cesarean delivery rate, childbirth is likely to have a huge impact on the occurrence of acute and possibly chronic postpartum pain. Recent awareness that
Intrathecal clonidine administration and erectile dysfunction: what is the link?
International journal of clinical pharmacology and therapeutics, 51(3), 255-262 (2013-02-06)
To assess the bioequivalence of two Tizanidine 4 mg tablet formulations (Tizanidine® of the Pharma International company, as test product, and Sirdalud® of Novartis as a reference product), and to investigate possible effects of smoking on pharmacokinetics of tizanidine. A
Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference, 2012, 3858-3861 (2013-02-01)
This study was to quantify the effects of Lokomat training on ambulation capacity of patients with incomplete spinal cord injury (SCI), and to examine the potential assistance of anti-spasticity medication on training. Twenty-nine SCI subjects with spastic hypertonia at their